Featured Research

from universities, journals, and other organizations

Removing Ovaries Before Menopause Can Lead To Memory And Movement Problems

Date:
August 30, 2007
Source:
American Academy of Neurology
Summary:
Women who have their ovaries removed before menopause are at an increased risk of developing memory problems or dementia and movement disorders such as Parkinson's disease, according to two new articles. Researchers found that women who had one or both ovaries removed before menopause were nearly two times more likely to develop cognitive problems or dementia compared to women who did not have the surgery. In addition, those women who were younger when their ovaries were removed were more likely to develop dementia than women who were older when their ovaries were removed.

Women who have their ovaries removed before menopause are at an increased risk of developing memory problems or dementia and movement disorders such as Parkinson's disease, according to two studies published August 29, 2007, in the online edition of Neurology®.

The study on dementia involved approximately 1,500 women who underwent the removal of one or both ovaries for non-cancer-related reasons, such as ovarian cysts, endometriosis, or for the prevention of ovarian cancer. The women were compared to an equal number of women who still had both ovaries at the beginning of the study. All participants were followed for a median of 27 years and were interviewed about their memory. If the women could not be interviewed directly, the investigators interviewed a family member.

Researchers found that women who had one or both ovaries removed before menopause were nearly two times more likely to develop cognitive problems or dementia compared to women who did not have the surgery. In addition, those women who were younger when their ovaries were removed were more likely to develop dementia than women who were older when their ovaries were removed.

"It's possible that estrogen has a protective effect on the brain and that a lack of estrogen due to ovary removal may increase a woman's risk of developing memory problems," said study author Walter A. Rocca, MD, MPH, with the Mayo Clinic in Rochester, MN, and member of the American Academy of Neurology.

Rocca says this is one of the first studies to show there may be a critical age window for the protective effect of estrogen on the brain in women. Before this study, knowledge was based almost exclusively on animal experiments. "For example, the study found women who had both ovaries removed before age 49, but were given estrogen treatment until at least age 50, did not have an increased risk of developing memory problems. These findings suggest that estrogen is protective for these women in this age window. By contrast, past studies from the Women's Health Initiative have shown that estrogen use started at age 65 years or later may have a negative effect on memory and may increase the risk of developing dementia," said Rocca.

Rocca says these findings have important clinical implications and should prompt physicians to reassess removing ovaries before menopause and the use of estrogen treatment following such surgery. "Although almost 60 percent of women received some estrogen treatment after both of their ovaries were removed, only 20 percent of them received estrogen treatment until at least age 50. Age 50 is the median age when women reach natural menopause."

Many of the women involved in the dementia study were also included in a larger study that found women who had one or more ovaries removed before menopause were nearly two times more likely to develop Parkinsonism, a syndrome involving tremor at rest, muscle rigidity, and slowness of movements. The most common form of this syndrome is Parkinson's disease. The risk for Parkinsonism increased with younger age at ovary removal. "Similar to the findings for dementia, these findings may be explained by a premature loss of estrogen and decreased neuroprotection," said Rocca.

Both studies were supported by grants from the National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases.


Story Source:

The above story is based on materials provided by American Academy of Neurology. Note: Materials may be edited for content and length.


Cite This Page:

American Academy of Neurology. "Removing Ovaries Before Menopause Can Lead To Memory And Movement Problems." ScienceDaily. ScienceDaily, 30 August 2007. <www.sciencedaily.com/releases/2007/08/070829162824.htm>.
American Academy of Neurology. (2007, August 30). Removing Ovaries Before Menopause Can Lead To Memory And Movement Problems. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2007/08/070829162824.htm
American Academy of Neurology. "Removing Ovaries Before Menopause Can Lead To Memory And Movement Problems." ScienceDaily. www.sciencedaily.com/releases/2007/08/070829162824.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins